Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00559377
Other study ID # NCI-2009-00257
Secondary ID NCI-2009-00257UW
Status Completed
Phase Phase 2
First received November 15, 2007
Last updated December 28, 2016
Start date November 2007
Est. completion date May 2014

Study information

Verified date December 2016
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well PET scans using fluoromisonidazole F 18 and fludeoxyglucose F 18 work in finding oxygen in tumor cells of patients undergoing treatment for newly diagnosed stage 1B, stage II, stage II, or stage IV cervical cancer. Diagnostic procedures using positron emission tomography (PET scan), fluoromisonidazole F 18, and fludeoxyglucose F 18 to find oxygen in tumor cells may help doctors predict how patients will respond to treatment.


Description:

PRIMARY OBJECTIVES:

I. Test the extent to which fluoromisonidazole F 18 ([^18F] FMISO) uptake predicts survival of patients undergoing therapy for newly diagnosed stage IB-IVB cervical cancer.

SECONDARY OBJECTIVES:

I. Test [^18F] FMISO tumor uptake as an independent predictor of response to therapy and that it provides additional predictive power over fludeoxyglucose F 18 ([^18F] FDG).

II. Test [^18F] FMISO tumor uptake as a predictor of response in a subgroup of patients receiving radiotherapy.

III. Test the relationship between [^18F] FMISO uptake in the primary tumor and the volume of the primary tumor estimated by CT scan.

IV. Test the reproducibility of [^18F] FMISO uptake in tumors by imaging the same patients on sequential days in a test-retest protocol.

V. Compare [^18F] FMISO PET or PET/CT scan with [^18F] FDG PET or PET/CT scan to test whether [^18F] FMISO is an independent predictor of treatment outcome.

OUTLINE:

Patients receive fluoromisonidazole F 18 ([^18F] FMISO) IV over 1 minute followed by PET scanning. Patients undergo a second [^18F] FMISO PET scan 4-8 weeks later. Patients who have not had a prior fludeoxyglucose F 18 ([^18F] FDG) PET scan as part of their routine clinical management undergo [^18F] FDG PET scanning at baseline. A subset of 10 patients undergo two [^18F] FMISO PET scans within a 48-hour period to evaluate the variability (test-retest) of this imaging measurement.

Patients response to therapy is followed periodically until time to disease progression or for 2 years.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date May 2014
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed squamous cell or adenocarcinoma of the uterine cervix

- Clinical stage IB-IVB by FIGO criteria

- Size of the primary tumor = 2 cm as assessed by CT scan

- Measurable disease

- Scheduled to undergo radiotherapy, chemotherapy, or combined multimodality management

- No prior cervical cancer diagnosis

- No known brain metastases

- ECOG performance status (PS) 0-2 (Karnofsky PS 60-100%)

- Life expectancy > 12 months

- Not pregnant

- No nursing for 24 hours after fluoromisonidazole F 18 ([^18F] FMISO) PET scanning

- Negative pregnancy test

- Weight = 400 lbs

- Sufficiently healthy to undergo cancer treatment

- Willing to undergo PET scanning with urinary bladder catheterization

- Leukocytes = 3,000/mm³

- Absolute neutrophil count = 1,500/mm³

- Platelet count = 100,000/mm³

- Total bilirubin normal

- AST/ALT = 2.5 times normal

- Creatinine normal OR creatinine clearance = 60 mL/min

- No serious medical co-morbidities that would preclude definitive local therapy

- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to [^18F] FMISO

- No concurrent uncontrolled illness including, but not limited to, any of the following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness/social situations that would limit compliance with study requirements.

- No prior surgery or radiotherapy for cervical cancer

- Other concurrent investigational agents allowed

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Intervention

Other:
18F-fluoromisonidazole
Undergo ^18F FMISO PET scan
Radiation:
fluorodeoxyglucose F 18
Undergo ^18F FDG PET scan
Procedure:
positron emission tomography
Undergo ^18F-FMISO and ^18F FDG PET scan
Other:
tissue oxygen measurement
Undergo ^18 F FMISO PET and ^18F FDG PET

Locations

Country Name City State
United States University of Washington Medical Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival (OS) Evaluate the value of pre-treatment FMISO results (T:B and HV) for all patients to predict the survival outcome variables. For up to 2 years No
Primary Disease-free Survival (DFS) Evaluate the value of pre-treatment FMISO results (T:B and HV) for all patients to predict the disease free survival outcome variables. Up to 2 years No
Secondary Relationship Between Hypoxia-related IHC Biomarkers and Regional FMISO Uptake in Tumor The value of the biomarker by IHC analyses relates primarily to validating the information content of FMISO images. Up to 2 years No
Secondary Relationship Between Ki67 and Regional FMISO Uptake in Tumor The value of the biomarker Ki67 analyses relates primarily to validating the information content of FMISO images. Up to 2 years No
Secondary Response to XRT Using RECIST Response for the XRT is evaluated by the radiation oncologists as per standard clinical protocols time to disease progression or 2 years following first FMISO scan No
See also
  Status Clinical Trial Phase
Completed NCT02562729 - Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Phase 2
Completed NCT00416455 - Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Phase 1/Phase 2
Completed NCT00054444 - Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer Phase 1
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Active, not recruiting NCT02140021 - Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer N/A
Completed NCT00068549 - Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer Phase 1
Completed NCT01711515 - Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer Phase 1
Terminated NCT00924066 - Ixabepilone to Treat Cervical Cancer Phase 2
Completed NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Active, not recruiting NCT05613283 - Primary Cervical Cancer Screening by Self-sampling HPV Test
Recruiting NCT03742869 - HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma
Withdrawn NCT03834571 - Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women Phase 2
Completed NCT01266460 - Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Completed NCT00064077 - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Phase 3
Active, not recruiting NCT02257528 - Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Phase 2
Active, not recruiting NCT02466971 - Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Phase 3
Completed NCT02164461 - Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Phase 1
Completed NCT01281852 - Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Phase 1
Active, not recruiting NCT04622670 - Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer N/A
Completed NCT02921269 - Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Phase 2